Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from BioCryst ( (BCRX) ) is now available.
On December 9, 2025, Nancy J. Hutson, Ph.D. announced her intention to retire from BioCryst Pharmaceuticals’ Board of Directors, effective by the earlier of the company’s 2026 annual meeting or the closing of its proposed acquisition of Astria Therapeutics. Dr. Hutson, who has served as Chair of the Board and various committees, cited no disagreements with the company. In response, the Board elected Vincent J. Milano as the next Chair, effective upon her retirement.
The most recent analyst rating on (BCRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
BioCryst’s overall stock score reflects significant financial challenges, despite positive strategic moves and technical indicators. The company’s high leverage and negative equity weigh heavily on its financial performance, but strong earnings call sentiment and corporate events provide a positive outlook.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on the development of oral and small-molecule medicines for rare diseases. The company’s market focus includes providing innovative treatments for conditions with significant unmet medical needs.
Average Trading Volume: 4,971,410
Technical Sentiment Signal: Sell
Current Market Cap: $1.61B
Learn more about BCRX stock on TipRanks’ Stock Analysis page.